Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03805594
Recruitment Status : Recruiting
First Posted : January 15, 2019
Last Update Posted : May 27, 2021
Sponsor:
Collaborators:
Prostate Cancer Foundation
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Rahul Aggarwal, University of California, San Francisco

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : August 31, 2022